<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01598844</url>
  </required_header>
  <id_info>
    <org_study_id>JV03PMS</org_study_id>
    <nct_id>NCT01598844</nct_id>
  </id_info>
  <brief_title>Longterm Safety and Performance of the JenaValve</brief_title>
  <acronym>JUPITER</acronym>
  <official_title>&quot;The JenaValve&quot; EvalUation of Long Term Performance and Safety In PaTients With SEvere Aortic Stenosis oR Aortic Insufficiency&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JenaValve Technology GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JenaValve Technology GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this registry is to observe longterm performance and safety of the JenaValve
      TAVI system, in routine medical and everyday conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the long term safety and effectiveness of the
      CE-marked JenaValve System Transapical in an elderly patient population with severe aortic
      stenosis and/or aortic insufficiency who are at high risk for open surgical aortic valve
      replacement.

      The target study population will consist of elderly patients suffering from severe
      symptomatic degenerative aortic valve stenosis and/or aortic insufficiency who show an
      increased risk for an open aortic valve replacement surgery due to existing co-morbidities.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>30 day</time_frame>
    <description>30-day mortality of procedure is defined as all deaths within 30 days after implantation of the JenaValve prosthesis irrespective of the underlying cause of death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoints</measure>
    <time_frame>peri- and post-operatively and at 3, 6, 12, 24 and 36 months</time_frame>
    <description>All-cause mortality,
Cardiovascular mortality,
Major stroke,
Life-threatening or disabling bleeding,
Major bleeding,
Acute kidney injury,
Myocardial infarction,
Major vascular complication,
Mechanical coronary obstruction,
Prosthetic valve thrombus,
Prosthetic valve endocarditis,
Conduction disturbance and cardiac arrhythmia,
Necessity of permanent pacemaker implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>Index Procedure and Immediate Post-operative</time_frame>
    <description>The following parameters will be collected to assess device success:
Successful vascular access, delivery and deployment of the device successful retrieval of the device
Correct position of the device in the proper anatomical location
Intended performance of the prosthetic heart valve:
Only one valve implanted in proper anatomical position</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>Prior to discharge, at 3, 6, 12, 24 and 36 months</time_frame>
    <description>The following parameters will assess effectiveness:
Transvalvular aortic peak pressure gradient
Transvalvular aortic mean pressure gradient
Effective aortic valve area
Paravalvular regurgitation coded according to VARC
Transvalvular regurgitation coded according to VARC
No clinically significant valve migration/dislocation
Absence of mechanical coronary obstruction
Functional improvement assessment by NYHA functional classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>at 12 months</time_frame>
    <description>The SF-12v2 Health Survey is an abbreviated version of the SF-36 Health Survey that uses 12 of the SF-36 items to measure functional health and well-being from the patient's point of view. The SF-12v2 is a practical, reliable, and valid measure of physical and mental health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined Safety Endpoint</measure>
    <time_frame>at 30 days</time_frame>
    <description>A combined safety endpoint will be assessed at 30 days consisting of the following variables:
All-cause mortality
Major stroke
Acute kidney injury (Stage 3)
Life-threatening or disabling bleeding
Major vascular complication
Peri-procedural myocardial infarction
Repeat surgical or interventional procedure for valve-related dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined Efficacy Endpoint</measure>
    <time_frame>at 12 months</time_frame>
    <description>A combined efficacy endpoint will be assessed consisting of the following variables:
All-cause mortality (after &gt; 30 days)
Failure of current therapy for AS, requiring hospitalization for symptoms of valve-related or cardiac decompensation
Prosthetic heart valve dysfunction</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">210</enrollment>
  <condition>Aortic Stenosis</condition>
  <condition>Aortic Insufficiency</condition>
  <arm_group>
    <arm_group_label>High risk patients with aortic stenosis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>High risk patients with AI</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter aortic valve replacement</intervention_name>
    <description>Transcatheter aortic valve replacement via a transapical access</description>
    <arm_group_label>High risk patients with aortic stenosis</arm_group_label>
    <arm_group_label>High risk patients with AI</arm_group_label>
    <other_name>The JenaValve TAVI System</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with severe aortic stenosis or with severe aortic insufficiency and an increased
        risk for an open aortic valve replacement surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients suitable for TAVI with the JenaValve according to instructions for use

        Exclusion Criteria:

          -  Patients unsuitable for TAVI with the JenaValve according to instructions for use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olaf Wendler, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College Hospital, London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hendrik Treede, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>UKE Hamburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Dresden, Universitätsklinik an der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Heart Centre</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäres Herzzentrum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum der Universität</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig - Universitätsklinik</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum des Städtischen Klinikums München</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Kreislaufzentrum Rotenburg (Fulda)</name>
      <address>
        <city>Rotenburg An Der Fulda</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Bosch Krankenhaus Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Silaschi M, Treede H, Rastan AJ, Baumbach H, Beyersdorf F, Kappert U, Eichinger W, Rüter F, de Kroon TL, Lange R, Ensminger S, Wendler O. The JUPITER registry: 1-year results of transapical aortic valve implantation using a second-generation transcatheter heart valve in patients with aortic stenosis. Eur J Cardiothorac Surg. 2016 Nov;50(5):874-881. Epub 2016 May 30.</citation>
    <PMID>27242354</PMID>
  </results_reference>
  <results_reference>
    <citation>Silaschi M, Conradi L, Wendler O, Schlingloff F, Kappert U, Rastan AJ, Baumbach H, Holzhey D, Eichinger W, Bader R, Treede H. The JUPITER registry: One-year outcomes of transapical aortic valve implantation using a second generation transcatheter heart valve for aortic regurgitation. Catheter Cardiovasc Interv. 2017 Nov 24. doi: 10.1002/ccd.27370. [Epub ahead of print]</citation>
    <PMID>29171730</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2012</study_first_submitted>
  <study_first_submitted_qc>May 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2012</study_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

